Insilico Medicine CEO to Keynote Morgan Stanley's China Biopharma Symposium on AI Drug Discovery

The Morgan Stanley China Biopharma Symposium will bring together global pharmaceutical leaders, Chinese biotech founders, academics, and healthcare investors. The event aims to promote cross-border collaboration and the international expansion of China’s biopharma innovations. Dr. Alex Zhavoronkov, CEO of Insilico Medicine, will deliver a keynote at the symposium on June 18, 2026. His presentation, titled 'AI-Driven Drug Discovery in China: Accelerating from Hit to Clinic', will highlight the company’s progress in using artificial intelligence to speed up drug development.

Since 2021, Insilico Medicine has nominated 31 preclinical candidate molecules. Of these, 13 have received Investigational New Drug (IND) approvals. The company’s platform combines disease data, molecular properties, and generative chemistry to design novel therapies for conditions like fibrosis, oncology, and immunology.

Its AI workflow operates as a closed-loop system. This means it continuously refines models by incorporating feedback from biological assays. Insilico Medicine recently listed on the Hong Kong Stock Exchange under the ticker 03696.HK. The symposium will explore how AI and international partnerships can advance Chinese biotech therapies. Insilico Medicine’s achievements in drug discovery and its market debut underscore the growing role of technology in pharmaceutical innovation.